mRNA flu shots move into trials
Elie Dolgin • Oct 11, 2021
COVID-19 provided an opportunity to show that mRNA vaccines can work. Now, drug companies are racing to apply the technology platform for influenza.
Hot off the successful deployment of mRNA vaccines for the prevention of COVID-19, three leading drugmakers have moved seasonal flu vaccine candidates built with the technology into early clinical testing.
Continue reading at Nature Reviews Drug Discovery.
Drug trial results show that vaccines aren't the only use for the mRNA technology behind the most widely used COVID-19 jabs.
FDA panel’s green light on glaucoma wearable device offers hope in sight.